Phase 2 N=12 Valchlor in the Treatment of Lichen Planopilaris
Lichen Planopilaris
Primary: Change in Lichen Planopilaris Activity Index (LLPAI) — -42.9; -66.7 percentage of change from baseline — p=0.014
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Lichen Planopilaris · Frontal Fibrosing Alopecia
Primary: Change in Patient-Reported Itch — -0.33 units on a scale
Phase 2 N=11 A Study of Deucravacitinib to Treat LPP and FFA
Lichen Planopilaris
Primary: Complete and Partial Response to Deucravacitinib Measured by Lichen Planopilaris Activity Index (LPPAI) Score — 9 Participants
Phase 2 N=12 Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus
Cutaneous Lichen Planus
Primary: Physician Global Assessment (PGA) of Skin Overall Response — 5; 5; 0; 0 Participants
Phase 2 N=12 Topical Ruxolitinib Lichen Planus
Lichen Planus
Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale
Phase 2 N=21 Pimecrolimus Cream for Oral Lichen Planus
Oral Lichen Planus
Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…
Phase 4 N=20 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Central Centrifugal Cicatricial Alopecia
Primary: Mean Change in Physician Global Assessment of Improvement (PGA-I) — 0.07 score on a scale
Phase 2 N=64 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
Cutaneous Lichen Planus
Primary: Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) at Week 16 — 50.0; 21.9 percentage of participants — p=0.0129
Phase 2 N=111 PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Primary: Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP — 44.0; 58.2; 37.5; 23.1 percentage of participants
Phase 4 N=28 A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus
Oral Lichen Planus
Primary: Change in Severity of Lesions(Degree of Reticular, Erythematous and Ulceration) by Using Piboonniyom REU Severity Score — 2.15; 0.73 Scores on a scale — p=0.004
Phase 3 N=23 Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.
Oral Lichen Planus · Oral Lichenoid Mucositis · Oral Lichenoid Reaction
Primary: Self-reported Pain Scores Using 100m Visual Analog Scale 0-100 Pain Score. — 6.4; 12.3 mm
N/A N=45 Alefacept in Patients With Severe Scalp Alopecia Areata
Alopecia Areata
Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…
N/A N=30 Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Number of Patients With SALT50 — 1; 1 Participants
N/A N=11 Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
Frontal Fibrosing Alopecia · Lichen Planopilaris of Scalp
Primary: Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) — 47.5; 44; 16.3; 15.9 score on a scale
Phase 2 N=51 Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Cicatricial Alopecia
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants
Phase 2 N=60 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale
Phase 3 N=718 PF-06651600 for the Treatment of Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 — 30.65; 22.31; 23.39; 14.29 Percentage of…
Phase 2 N=24 Dexamethasone Solution for the Treatment of Oral Lichen Planus
Lichen Planus
Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale
Phase 2 N=31 LEO 124249 Ointment in the Treatment of Alopecia Areata
Alopecia Areata
Primary: Change in Severity of Alopecia Areata Tool (SALT) Score — -3.8; -3.4 units on a scale — p=0.97
Phase 2 N=12 Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Clinical Improvement in PRP Severity and Body Surface Area — 15.2 units on a scale — p=<0.001
Phase 2 N=22 A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Change in Gene Expression Th2/IL-13, "T22"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL-17A Jointly Correlated — -0.28 z-score
Phase 3 N=52 Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus
Vulvar Lichen Sclerosus
Primary: Change in SkinDEX-29 Score — -16.83; -5.92 score on a scale — p=0.007
Phase 3 N=40 Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus
Oral Lichen Planus
Primary: Pain — 0; 4; 4.4 units on a scale
N/A N=30 The Effect of Platelet Rich Plasma on Non-scarring Alopecia
Androgenetic Alopecia · Alopecia
Primary: Number of Participants With Improvement — 8; 1 Participants
N/A N=30,901 Healthcare Disparities in Alopecia Areata
Alopecia Areata
Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants
Phase 2 N=20 A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
Oral Lichen Planus
Primary: Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP) — -22; 0; -17; 0 percent change
N/A N=24 A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
Central Centrifugal Cicatricial Alopecia
Primary: Shape of the Hairline Documented With Photographs — 8; 12; 2 Participants
Phase 2 N=14 Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI
Phase 2 N=61 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Lichen Sclerosus
Primary: Percentage of Participants With ITCH4 at Week 12 — 35.7; 40.0 percentage of participants — p=0.737
Phase 2 N=30 Tofacitnib for the Treatment of Alopecia Areata and Variants
Alopecia Areata (AA) · Alopecia Totalis (AT) · Alopecia Universalis (AU)
Primary: Mean Change in Severity of Alopecia Tool (SALT) Score — 22.8 percent change in SALT score